Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

[Comparison of peg-interferon monotherapy to peg-interferon and nucleoside analogue combination therapy for hepatitis B: a meta-analysis of randomized controlled trials].

Li MY, Yuan XL, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Jun;20(6):442-7. doi: 10.3760/cma.j.issn.1007-3418.2012.06.013. Chinese.

PMID:
23044202
2.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

3.

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.

Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A.

Health Technol Assess. 2009 Jul;13(35):1-172, iii. doi: 10.3310/hta13350. Review.

4.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270
5.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
6.

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.

Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.

J Gastroenterol Hepatol. 2010 Jan;25(1):54-60. doi: 10.1111/j.1440-1746.2009.05952.x. Epub 2009 Sep 22.

PMID:
19780875
7.

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.

Antivir Ther. 2009;14(8):1165-74. doi: 10.3851/IMP1466.

PMID:
20032546
8.

[Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients].

Ma XJ, Chen XP, Chen XF, Chen WL, Huang J, Chen R, Luo XD, Ma HY.

Zhonghua Gan Zang Bing Za Zhi. 2012 Feb;20(2):98-102. doi: 10.3760/cma.j.issn.1007-3418.2012.02.006. Chinese.

PMID:
22464779
10.

A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.

Wei W, Wu Q, Zhou J, Kong Y, You H.

Int J Environ Res Public Health. 2015 Aug 21;12(8):10039-55. doi: 10.3390/ijerph120810039.

11.

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review.

Zhang Y, Chen B, Wang L, Chi J, Song S, Liu M, Zhao Z.

Rev Esp Enferm Dig. 2016 May;108(5):263-70. doi: 10.17235/reed.2016.3995/2015. Review.

12.

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.

J Hepatol. 2010 Sep;53(3):449-54. doi: 10.1016/j.jhep.2010.03.020. Epub 2010 May 25.

PMID:
20646776
13.
14.

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.

Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H.

Virol J. 2011 Aug 8;8:393. doi: 10.1186/1743-422X-8-393. Review.

15.

Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.

Wang LC, Chen EQ, Cao J, Liu L, Wang JR, Lei BJ, Tang H.

J Viral Hepat. 2010 Mar;17(3):178-84. doi: 10.1111/j.1365-2893.2009.01164.x. Epub 2009 Jul 28.

PMID:
19656287
16.
17.

Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study.

Aizawa M, Tsubota A, Fujise K, Sato K, Baba M, Takamatsu M, Namiki Y, Ohkusa T, Tajiri H.

Intern Med. 2010;49(12):1067-72. Epub 2010 Jun 15.

18.

Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.

Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z.

Intern Med. 2012;51(12):1509-15. Epub 2012 Jun 15.

19.

A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.

Takeda A, Jones J, Shepherd J, Davidson P, Price A.

J Viral Hepat. 2007 Feb;14(2):75-88. Review.

PMID:
17244247
20.

Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.

Chen EQ, Wang LC, Lei J, Xu L, Tang H.

Virol J. 2009 Oct 9;6:163. doi: 10.1186/1743-422X-6-163. Review.

Supplemental Content

Support Center